Cardium Therapeutics (CXM) Reports In-Line Q1 Loss of 2c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CXM Hot Sheet
Price: $6.88 +1.03%
EPS Growth %: -8.3%
Financial Fact:
Loss per common share - basic and diluted: -0.14
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: -8.3%
Financial Fact:
Loss per common share - basic and diluted: -0.14
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Cardium Therapeutics, Inc. (NYSE: CXM) reported Q1 EPS of ($0.02), versus ($0.02) reported last year.
For earnings history and earnings-related data on Cardium Therapeutics, Inc. (CXM) click here.
For earnings history and earnings-related data on Cardium Therapeutics, Inc. (CXM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Pampa EnergÃa S.A. (PAM) Misses Q3 EPS by 240c
- Upwork Inc. (UPWK) Tops Q3 EPS by 8c; Offer Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
